首页> 外文会议>Optical Methods for Tumor Treatment and Early Diagnosis: Mechanisms and Techniques >Histochemical identification of malignant and premalignant lesions
【24h】

Histochemical identification of malignant and premalignant lesions

机译:恶性和恶变前病变的组织化学鉴定

获取原文
获取原文并翻译 | 示例

摘要

Abstract: Malignant and transforming cells can be identified by biochemical parameters which can be used to localize lesions in situ for laser surgery. These cells express unique proteins, proteins in unusual quantities, or other biochemical alterations which can be utilized to image lesions of such cells. Several methods have been identified, both in vitro and in vivo, to identify such lesions. Several antibodies were examined for their properties of tissue identification, including CEA, F36/22, and AE1/AE3. F36/22, an antibody developed by M. T. Chu against human breast cancer cells, associated with two lines of oral cancer (KB and HCPC), and against two naturally occurring human oral squamous cell cancers. CEA, an antibody developed against human colon cancer, also reacted against both cell lines and both pathological samples. AE1/AE3, developed against normal fibrous components, also reacted against the samples, but in a much less regular manner. F36/22 associated with the histologically identifiably most dedifferentiated cells at the leading edge of the invading cancer. CEA, on the other hand, associated with more quiescent, older, established cancer cells. This demonstrates that antibodies developed against cancers of different organs can be used to identify a wide variety of cancers, and may have prognostic value. F36/22 coupled to fluorescein was used to identify oral cancer cells. Other properties of cancers and developing cancers can also be exploited to identify cancers, including their over-expression of tyrosine kinase and tyrosine kinase stimulating hormones such as Epidermal Growth Factor (EGF). A model of premalignant lesion produced in the hamster buccal cheek pouch with 6 week application of DMBA over-expresses constitutive tyrosine kinase which can be demonstrated biochemically. This initiated lesion can be promoted to frank cancer by growth factors released in response to laser surgery. Preliminary results suggest that these lesions can be identified by Photofrin II uptake. This work suggests that biochemical properties of cancers can be used to identify premalignant cells.!
机译:摘要:恶性和转化细胞可以通过生化参数进行鉴定,这些参数可用于激光手术原位定位病变。这些细胞表达独特的蛋白质,异常数量的蛋白质或其他可用于成像此类细胞病变的生化改变。已经在体外和体内鉴定了几种方法来鉴定此类损伤。检查了几种抗体的组织鉴定特性,包括CEA,F36 / 22和AE1 / AE3。 F36 / 22,一种由M. T. Chu开发的针对人类乳腺癌细胞的抗体,与两种口腔癌(KB和HCPC)有关,并且针对两种天然存在的人类口腔鳞状细胞癌。 CEA,一种针对人类结肠癌的抗体,也对两种细胞系和两种病理样品都产生了反应。针对正常纤维成分而产生的AE1 / AE3也与样品发生反应,但规律性较差。 F36 / 22与在侵袭性癌症的前沿组织学上可识别的大多数去分化细胞有关。另一方面,CEA与更静止,更老的成熟癌细胞相关。这表明针对不同器官的癌症开发的抗体可用于鉴定多种癌症,并可能具有预后价值。 F36 / 22与荧光素偶联用于鉴定口腔癌细胞。也可以利用癌症和发展中癌症的其他特性来鉴定癌症,包括它们过度表达酪氨酸激酶和酪氨酸激酶刺激激素,例如表皮生长因子(EGF)。施用DMBA 6周后,在仓鼠颊颊袋中产生的恶变前病变模型过表达组成性酪氨酸激酶,这可以通过生物化学方法证实。可以通过响应激光手术释放的生长因子来促进这种起始病变,从而促进癌症的发生。初步结果表明,可以通过摄取Photofrin II来识别这些病变。这项工作表明,癌症的生化特性可用于鉴定癌前细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号